Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery
- PMID: 12478413
- DOI: 10.1007/s00147-002-0491-0
Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery
Abstract
Neoral cyclosporine has better absorption characteristics than the original Sandimmun formulation. This has allowed Neoral to be administered orally in circumstances where Sandimmun had been ineffective, including the postoperative phase of liver transplantation. Sampling strategies, such as the measurement of drug concentration 2 h after oral administration, have been used in a variety of settings to estimate systemic exposure to Neoral (measured as the area under the blood concentration curve (AUC) of the drug) in blood. We conducted a pilot study to determine whether Neoral could be administered orally immediately after heart transplantation and to determine which pharmacokinetic parameters reflect systemic drug exposure in this setting. Eight male patients (mean age 50 years) undergoing a first heart transplant were studied. Neoral was administered orally before surgery and at 12-h intervals via a nasogastric tube after surgery. Twelve-hour pharmacokinetic profiles were obtained on postoperative days 1, 3 and 5. Cyclosporine concentrations were measured with the Dade Behring Emit assay, which is specific for the parent drug. Drug concentrations were dose-normalised and drug exposure was measured by the AUC. Drug exposure following administration (AUC(0-12)) was low on day 1 but increased by 99% between postoperative day 1 and day 5 ( P<0.05), indicating more complete absorption of cyclosporine; exposure in the first 4 h post-dose (AUC(0-4)) increased by 126% ( P<0.01), reflecting more rapid cyclosporine absorption, and the maximum blood concentration observed increased by 137% ( P<0.05) during the same period. The correlation between the cyclosporine trough concentration and AUC(0-12) was low on all days. Due to the changing pattern of cyclosporine absorption, concentration measurements at a single time point could not accurately predict 12-h exposure to the drug on all study days. However, the drug concentration at 2 h post-dose had a high correlation with drug exposure during the first 4 h (correlation of C(2) to AUC(0-4): r(2)>0.93 on all days). Absorption of Neoral was low immediately after heart transplantation but improved substantially during the first 5 days after surgery. No single timed measurement of drug concentration reflected cyclosporine exposure; however, the 2-h concentration did provide an accurate measure of the early phase of drug absorption (AUC(0-4)). Oral administration of Neoral may result in inadequate immunosuppression immediately after heart transplantation unless it is supplemented either by intravenous cyclosporine or by the use of an induction agent.
Similar articles
-
Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.Bone Marrow Transplant. 2000 Sep;26(5):545-51. doi: 10.1038/sj.bmt.1702545. Bone Marrow Transplant. 2000. PMID: 11019845
-
A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.Clin Ther. 2006 Jun;28(6):893-905. doi: 10.1016/j.clinthera.2006.06.015. Clin Ther. 2006. PMID: 16860172
-
How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?Clin Transplant. 1998 Oct;12(5):379-90. Clin Transplant. 1998. PMID: 9787945 Clinical Trial.
-
Neoral in liver transplantation.Transplant Proc. 1996 Apr;28(2):1019-21. Transplant Proc. 1996. PMID: 8623216 Review.
-
Evolution of the therapeutic drug monitoring of cyclosporine.Transplant Proc. 2004 Mar;36(2 Suppl):420S-425S. doi: 10.1016/j.transproceed.2004.01.054. Transplant Proc. 2004. PMID: 15041378 Review.
Cited by
-
Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients.Drug Des Devel Ther. 2014 Nov 7;8:2241-9. doi: 10.2147/DDDT.S70595. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25422583 Free PMC article.
-
Development and validation of an LC-MS/MS method for highly concentrated tacrolimus and cyclosporine samples prepared from pharmaceutical products to assess drug loss from feeding tubes.J Mass Spectrom Adv Clin Lab. 2024 Oct 9;34:28-33. doi: 10.1016/j.jmsacl.2024.10.002. eCollection 2024 Nov. J Mass Spectrom Adv Clin Lab. 2024. PMID: 39502200 Free PMC article.
-
Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients.Exp Ther Med. 2018 Nov;16(5):4265-4270. doi: 10.3892/etm.2018.6711. Epub 2018 Sep 10. Exp Ther Med. 2018. PMID: 30402164 Free PMC article.
-
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.Clin Pharmacokinet. 2008;47(7):449-62. doi: 10.2165/00003088-200847070-00002. Clin Pharmacokinet. 2008. PMID: 18563954 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous